Evidence map›Paper›PMID 33667282›Full record

ArticlePloS one2021

Assessment of the effect of therapy in a rat model of glioblastoma using [18F]FDG and [18F]FCho PET compared to contrast-enhanced MRI.

Julie Bolcaen, Benedicte Descamps, Karel Deblaere, Filip De Vos, Tom Boterberg, Giorgio Hallaert, Caroline Van den Broecke, Christian Vanhove, Ingeborg Goethals

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Performance ofBMC medical imaging · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Julie BolcaenRadiation Biophysics Division, Department of Nuclear Medicine, National Research Foundation iThemba LABS, Faure, South Africa.ORCID 0000-0001-8554-280X
Benedicte DescampsDepartment of Electronics and Information Systems, IBiTech-MEDISIP, Ghent University, Ghent, Belgium.ORCID 0000-0001-8879-1772
Karel DeblaereDepartment of Radiology, Ghent University Hospital, Ghent, Belgium.
Filip De VosDepartment of Radiopharmacy, Ghent University, Ghent, Belgium.
Tom BoterbergDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Giorgio HallaertDepartment of Neurosurgery, Ghent University Hospital, Ghent, Belgium.
Caroline Van den BroeckeDepartment of Pathology, Ghent University Hospital, Ghent, Belgium.
Christian VanhoveDepartment of Electronics and Information Systems, IBiTech-MEDISIP, Ghent University, Ghent, Belgium.
Ingeborg GoethalsDepartment of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
Ghent University Hospital · BEGhent University · BENational Research Foundation · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe investigated the potential of [18F]fluorodeoxyglucose ([18F]FDG) and [18F]Fluoromethylcholine ([18F]FCho) PET, compared to contrast-enhanced MRI, for the early detection of treatment response in F98 glioblastoma (GB) rats.

methodsWhen GB was confirmed on T2- and contrast-enhanced T1-weighted MRI, animals were randomized into a treatment group (n = 5) receiving MRI-guided 3D conformal arc micro-irradiation (20 Gy) with concomitant temozolomide, and a sham group (n = 5). Effect of treatment was evaluated by MRI and [18F]FDG PET on day 2, 5, 9 and 12 post-treatment and [18F]FCho PET on day 1, 6, 8 and 13 post-treatment. The metabolic tumor volume (MTV) was calculated using a semi-automatic thresholding method and the average tracer uptake within the MTV was converted to a standard uptake value (SUV).

resultsTo detect treatment response, we found that for [18F]FDG PET (SUVmean x MTV) is superior to MTV only. Using (SUVmean x MTV), [18F]FDG PET detects treatment effect starting as soon as day 5 post-therapy, comparable to contrast-enhanced MRI. Importantly, [18F]FDG PET at delayed time intervals (240 min p.i.) was able to detect the treatment effect earlier, starting at day 2 post-irradiation. No significant differences were found at any time point for both the MTV and (SUVmean x MTV) of [18F]FCho PET.

conclusionsBoth MRI and particularly delayed [18F]FDG PET were able to detect early treatment responses in GB rats, whereas, in this study this was not possible using [18F]FCho PET. Further comparative studies should corroborate these results and should also include (different) amino acid PET tracers.

Indexed as

GlioblastomaMagnetic Resonance ImagingNeoplasms, ExperimentalPositron-Emission TomographyAnimalsCell Line, TumorCholineContrast MediaFemaleFluorodeoxyglucose F18RatsRats, Inbred F344CholineContrast MediaFluorodeoxyglucose F18fluoromethylcholine

Identifiers

PMID33667282
PMCPMC7935304
OpenAlexW3134899111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.